pharmaphorum January 17, 2025
In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will support its vision of developing multiple personalised therapies for cardiovascular diseases.
Formed by former executives from MyoKardia – bought by Bristol Myers Squibb for $13.1 billion in 2020 – Kardigan says it has already curated a portfolio of “late-stage clinical candidates” that can be matched to patients who will be most likely to respond to them.
There’s not much detail on those candidates at the moment, but the San Francisco and Princeton-based start-up says they will include drugs for “primary and secondary cardiomyopathies leading to heart failure,” while it also intends to look at strategic licensing deals and acquisitions.
...Today's Sponsors
Today's Sponsor